Introduction
Status epilepticus (SE) is the most frequent neurological emergency requiring admission to a hospital and often times to an intensive care unit (ICU). 1 Untreated, SE can cause serious brain damage and possibly death. Chances of treatment failure of SE rise and prognosis deteriorates with increasing duration of SE, especially if duration exceeds 1 h. 2 Refractory generalized convulsive status epilepticus (RGCSE), defined as SE that fails to respond to the acute administration of two antiepileptic drugs (AEDs), occurs in approximately one third of patients with SE, and is associated with increased hospital length of stay, mortality, and functional disability. 3 Therefore, rapid treatment of SE is crucial in preventing severe morbidity and mortality; however, this may result in severe iatrogenic complications. Third-line therapies for SE with sedating or anesthetic effects predict poor outcome and death in status epilepticus. Hypotension requiring vasopressor therapy and longer duration of mechanical ventilation induced by these agents may be contributing factors. 4 Of course outcome is linked to etiology as well. Good outcome even after prolonged treatment of RGCSE have been reported in some patients. 3 Therefore, having more therapeutic options for SE, particularly novel treatment options with more favorable adverse-effect profiles are warranted. Topiramate is a widely used second generation, broadspectrum AED with a favorable pharmacological profile (e.g., absorption is rapid after enteral administration with peak serum concentration 1-4 h after administration). Topiramate blocks voltage-sensitive sodium channels. Topiramate also enhances the activity of GABA at GABA-A receptors by increasing the Purpose: To explore the feasibility, safety and efficacy of enterally administered topiramate (TPM) as an adjunctive treatment for adult patients with refractory generalized convulsive status epilepticus (RGCSE).
Methods:
This prospective open-label non-randomized clinical trial was performed at Namazee hospital, Shiraz University of Medical Sciences, Shiraz, Iran from January 2013 through February 2014. Patients 18 years of age and older with RGCSE were enrolled. Topiramate was used, in case of failure of at least two standard anti-epileptic drugs in patients in whom the standard third or fourth line therapies were not available. Topiramate tablets were crushed and administered through the nasogastric tube; 400 mg stat and then 200 mg Bid. Status epilepticus response to TPM was categorized as successful (termination of SE within 24 h following TPM introduction, without modification of concomitant AEDs), possible (SE termination associated with the introduction of TPM, concomitantly with other medications) or unsuccessful. Results: Twenty patients were studied. Topiramate was successful in terminating SE in five (25%) patients; possibly successful in 11 (55%); and not successful in four (20%). No clinically significant adverse effects related to TPM administration were observed. Eleven (55%) patients returned to their baseline clinical condition at the time of discharge from the hospital, but two (10%) patients did not. Conclusion: Treatment with enterally administered topiramate could potentially be efficacious in some patients and appeared to be tolerated well in patients with RGCSE. Low cost and feasibility makes TPM a potentially useful agent in treating patients with RGCSE, especially in resource limited settings.
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frequency at which GABA activates GABA-A receptors. In addition, topiramate inhibits excitatory transmission by antagonizing some types of glutamate receptors. It may also potentiate ATP activated inward rectifying potassium channels. Topiramate is also a weak carbonic anhydrase inhibitor.
5
A small number of reports have described the use of topiramate (TPM) in RGCSE in adults and in children. [6] [7] [8] The aim of the current study was to explore the feasibility, safety profile and efficacy of enterally administered topiramate as an adjunctive treatment for adult patients with RGCSE, especially when the resources are limited.
Materials and methods
This prospective single center open-label non-randomized clinical trial was performed at Namazee hospital, Shiraz University of Medical Sciences, Shiraz, Iran from January 2013 through February 2014. In this study, patients 18 years of age and older with RGCSE were enrolled. Status epilepticus was defined as the clinical occurrence of an ongoing seizure for more than 5 min or repeated seizures without full recovery in between for more than 30 min. 9 All patients underwent EEG (at least one 20-min EEG), which was performed the day after hospital admission and later on, due to shortage of personnel in the afternoon and night shifts. All patients underwent brain imaging (CT scan or MRI); laboratory work-up and cerebro-spinal fluid (CSF) analysis was performed as needed. Status epilepticus termination was defined as resolution of clinical ictal signs (i.e., cessation of motor activity and improvement in responsiveness) and confirmed with the disappearance of continuous or repetitive epileptiform discharges on the EEG, assessed at least daily. Topiramate was used as an add-on treatment, in case of failure of two standard AEDs (i.e., intravenous diazepam and phenytoin) and after 30-40 min from the second line (i.e., 10 min after infusion of phenytoin had completed), in patients in whom the standard third line therapy (i.e., intravenous phenobarbital or valproate) was not available or possible (e.g., due to costs, contraindications, etc.), or ICU was not accessible to start the line four of therapy (i.e., intravenous midazolam, propofol, or pentobarbital). Topiramate tablets were crushed and administered through the nasogastric tube. Topiramate dose was 400 mg stat and then 200 mg twice per day, starting 12 h after the bolus dose. Status epilepticus response to TPM was categorized as successful (termination of SE within 24 h following TPM introduction, without modification of concomitant AEDs), possible (SE termination associated with the introduction of TPM, concomitantly with other medications, in case the third line and/or the fourth line of therapy become available after introduction of TPM and within 24 h) or unsuccessful (no response to TPM treatment after 24 h). In patients in whom TPM was successful to stop SE after the 1st (diazepam) and the 2nd (phenytoin) line of treatment failed, we did not prescribe standard third or fourth line of therapy. We prescribed the standard third (i.e., phenobarbital or valproate) or fourth line (i.e., midazolam, propofol, or pentobarbital) therapy at any time, if they became available and the seizures were still ongoing. Successful and possible responses imply that SE does not recur during the same hospitalization. In successful and possible responses, the patient was discharged with TPM 100 mg twice per day for at least 1 month, along with other required therapies (either AEDs or others as needed). Outcome was assessed at the time of discharge from hospital, and categorized as return to the baseline clinical condition, new handicap, or death. The recorded variables included: age, gender, previous epilepsy, other etiology of SE, time to response after TPM administration, TPM success, side effects (e.g., metabolic acidosis, hemodynamic problems, renal stone, etc.), and outcome at discharge. Cognitive side effects and minor adverse effects (e.g., gastro-intestinal upset) of TPM were not studied. This study was conducted in accordance with local ethical regulations with approval by Shiraz University of Medical Sciences Review Board and Ethics Committee (IRCT # 16520 and grant # 90-01-55-2947). All primary care-givers of the patients consented in writing to their participation, after the scope of the study has been explained in a form understandable to them. The collected data was kept confidential through codes. All care-givers of the patients were advised that TPM was not an approved therapy for SE. They were informed of possible adverse drug effects related to TPM.
Results
Twenty patients (14 males and 6 females) were enrolled in the study. The minimum age of the patients was 18 years and the maximum age was 92 (mean = 44.45 and standard deviation = 23.15 years). The clinical characteristics of the patients are shown in Table 1 . Four patients were known cases of epilepsy and the remaining had new onset epileptic seizures (presenting as SE). None of the patients with epilepsy were receiving topiramate before. The etiology of SE was as follows: cerebrovascular accidents in four people, neurosurgical conditions in four patients [head injury (in two), brain tumor, subdural empyema], preexisting epilepsy in four cases (in three patients due to stopping their medication and in one due to change in medication by the treating physician), underlying medical conditions in three patients (liver transplantation, myocardial infarction and hepatic encephalopathy), unidentified etiology in three cases, hypoxic brain damage in one and post-operative SE in one patient.
Topiramate was successful in terminating RGCSE in five (25%) patients. Status epilepticus stopped after 42 AE 12 min (median: 45 min, range: 30-60 min) from administration of TPM in these five patients. Topiramate was possibly successful in stopping SE in 11 (55%) patients. Status epilepticus stopped after 148 AE 152 min from administration of TPM in these patients (range: 45-480 min). Topiramate was not successful in stopping SE in four (20%) patients. We did not observe any clinically significant adverse effects related to TPM administration in these patients. Thirteen patients (65%) needed intratracheal intubations (due to prolonged convulsions and hemodynamic instability or alternatively drug side effects). None of the patients had cardiac arrhythmia or change in blood pressure during intravenous phenytoin therapy. Later hemodynamic instability in the above-mentioned patients was attributed to the prolonged duration of status epilepticus, side effects of other prescribed drugs (e.g., phenobarbital or midazolam) or the underlying etiology (e.g., cerebrovascular accident or hepatic encephalopathy). Eleven (55%) patients returned to their baseline clinical condition at the time of discharge from hospital. Two (10%) patients did not return to their baseline clinical condition at the time of discharge from hospital and suffered some neurological sequelae. Unfortunately, seven (35%) patients died during their hospital stay. Four patients were nonresponders, who died of refractory seizures. Two patients were among possible responders; one of them died due to renal failure and pneumonia and another patient died because of end-stage pancreatic cancer. One patient, who was a responder, died of pneumonia and respiratory failure. In other words, mortality was 20% (one out of five) among responders and 18% (2 out of 11) among possible responders. Mortality was 100% (four out of four) among non-responders.
Discussion
Management of refractory SE is often challenging with disappointing results in some patients and significant morbidity (either treatment related or disease related) and even mortality in Mortality of the patients with RSE was 35% in our study that is similar to some previous studies 6 and is much higher than other reports. 7 Mortality is not strictly dependent on failure to terminate RGCSE, but also on the underlying etiology of RGCSE. This could explain the observed disparity between various studies. However, we observed that mortality was significantly higher if patients did not respond to topiramate.
Conclusion
Treatment with enterally administered topiramate could potentially be efficacious in some patients and appeared to be tolerated well in patients with RGCSE. Low cost and feasibility (route of administration and desirable pharmacological profile, including adverse effects) makes TPM a potentially useful agent in treating patients with RGCSE, in resource limited settings, in which the standard third line therapy is not accessible, or facilities (e.g., ICU) are not available to start the next lines of standard therapy.
Limitations of the study
The number of patients studied was small and this was not a double blind randomized clinical trial. We did not have access to continuous EEG monitoring to ascertain the seizure termination electrophysiologically.
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